Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia

Abstract

We performed a retrospective analysis to investigate dynamic peri-hematopoietic stem cell transplantation (HSCT) minimal/measurable residual disease (MRD) on outcomes in patients with T-cell acute lymphoblastic leukemia (T-ALL). A total of 271 patients were enrolled and classified into three groups: unchanged negative MRD pre- and post-HSCT group (group A), post-MRD non-increase group (group B), and post-MRD increase group (group C). The patients in group B and group C experienced a higher cumulative incidence of relapse (CIR) (42% vs. 71% vs. 16%, P<0.001) and lower leukemia-free survival (LFS) (46% vs. 21% vs. 70%, P<0.001) and overall survival (OS) (50% vs. 28% vs. 72%, P<0.001) than in group A, but there was no significant difference in non-relapse mortality (NRM) among three groups (14% vs. 12% vs. 8%, P=0.752). Multivariate analysis showed that dynamic peri-HSCT MRD was associated with CIR (HR=2.392, 95% CI, 1.816–3.151, P<0.001), LFS (HR=1.964, 95% CI, 1.546–2.496, P<0.001) and OS (HR=1.731, 95% CI, 1.348–2.222, P<0.001). We also established a risk scoring system based on dynamic peri-HSCT MRD combined with remission status pre-HSCT and onset of chronic graft-versus-host disease (GVHD). This risk scoring system could better distinguish CIR (c=0.730) than that for pre-HSCT MRD (c=0.562), post-HSCT MRD (c=0.616) and pre- and post-MRD dynamics (c=0.648). Our results confirm the outcome predictive value of dynamic peri-HSCT MRD either alone or in combination with other variables for patients with T-ALL.

Keywords

peri-transplantation minimal residual disease / risk stratification / risk scoring system / T-cell acute lymphoblastic leukemia

References

[1] WangY, LiuQF, XuLP, et al.. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clin Cancer Res, 2016, 22(14): 3467-3476

[2] ZhaoXS, LiuYR, XuLP, et al.. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol, 2019, 94(4): 512-521

[3] PuiCH, PeiD, Coustan-SmithE, et al.. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol, 2015, 16(4): 465-474

[4] SunYQ, LiSQ, ZhaoXS, et al.. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Rev Anticancer Ther, 2020, 20(6): 453-564

[5] ChangYJ, ZhaoXY, HuangXJ. Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Front Immunol, 2019, 10: 2516

[6] HayKA, GauthierJ, HirayamaAV, et al.. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133(15): 1652-1663

[7] ModvigS, MadsenHO, SiitonenSM, et al.. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia, 2019, 33(6): 1324-1336

[8] MalardF, MohtyM. Acute lymphoblastic leukaemia. Lancet, 2020, 395(10230): 1146-1162

[9] BurnsMA, PlaceAE, StevensonKE, et al.. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer, 2021, 68(1): e28719

[10] XuM, LiuH, LiuY, et al.. Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia. Leuk Lymphoma, 2019, 60(11): 2744-2753

[11] BaderP, KreyenbergH, von StackelbergA, et al.. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol, 2015, 33(11): 1275-1284

[12] BaderP, Salzmann-ManriqueE, BalduzziA, et al.. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv, 2019, 3(21): 3393-3405

[13] EckertC, HagedornN, SramkovaL, et al.. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia, 2015, 29(8): 1648-1655

[14] ZhaoX, HongY, QinY, et al.. The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol, 2017, 39(6): 613-619

[15] LiSQ, FanQZ, XuLP, et al.. Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Front Oncol, 2020, 10: 320

[16] WangXY, FanQZ, XuLP, et al.. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom, 2020, 98(1): 75-87

[17] ChangYJ, WangY, XuLP, et al.. Haploidentical donor is preferred over matched sibling donor for pretransplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol, 2020, 13(1): 27

[18] TeacheyDT, PuiCH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol, 2019, 20(3): e142-e54

[19] CaoLQ, ZhouY, LiuYR, et al.. A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chin Med J (Engl), 2021, 134(10): 1199-1208

[20] LovisaF, ZeccaM, RossiB, et al.. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol, 2018, 180(5): 680-693

[21] ZhaoXS, LiuYR, ZhuHH, et al.. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol, 2012, 91(2): 183-192

[22] Quist-PaulsenP, ToftN, HeymanM, et al.. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 2020, 34(2): 347-357

[23] TembharePR, NarulaG, KhankaT, et al.. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. Front Oncol, 2020, 10: 577

[24] BrammerJE, SalibaRM, JorgensenJL, et al.. Multicenter analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant, 2017, 52(1): 20-27

[25] SuttonR, ShawPJ, VennNC, et al.. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol, 2015, 168(3): 395-404

[26] YeshurunM, WeisdorfD, RoweJM, et al.. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv, 2019, 3(4): 670-680

[27] TerweyTH, Le DucTM, HemmatiPG, et al.. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol, 2013, 24(5): 1363-1370

[28] van RoodJJ, OudshoornM. When selecting an HLA mismatched stem cell donor consider donor immune status. Curr Opin Immunol, 2009, 21(5): 538-543

[29] BallenKK, KorethJ, ChenYB, et al.. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood, 2012, 119(9): 1972-1980

[30] HuangXJ, LiuDH, LiuKY, et al.. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant, 2009, 15(2): 257-265

[31] ChangYJ, XuLP, WangY, et al.. Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol, 2016, 34(16): 1855-1863

[32] ChangYJ, WuDP, LaiYR, et al.. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. J Clin Oncol, 2020, 38(29): 3367-3376

[33] ShulmanHM, CardonaDM, GreensonJK, et al.. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant, 2015, 21(4): 589-603

[34] International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol, 2016, 17(6): 779-790

[35] GuoH, ChangYJ, HongY, et al.. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol, 2021, 18(5): 1172-1185

[36] WalterRB, AppelbaumFR. Next-generation sequencing for measuring minimal residual disease in AML. Nat Rev Clin Oncol, 2018, 15(8): 473-474

[37] LiuJ, MaR, LiuYR, et al.. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant, 2019, 54(4): 567-577

[38] ZhouY, OthusM, ArakiD, et al.. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia, 2016, 30(7): 1456-1464

[39] EnshaeiA, O’ConnorD, BartramJ, et al.. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood, 2020, 135(17): 1438-1446

[40] GabelliM, VeysP, ChiesaR. Current status of umbilical cord blood transplantation in children. Br J Haematol, 2020, 190(5): 650-683